ArticleCancer discovery2020
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 148 citations in OpenAlex.
- CDK8 remodels the tumor microenvironment and promotes resistance to KRASThe EMBO journal · 2026Article
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- The impactful role of the HDACs in the regulation of gene expression and as targets for disease therapy.Science advances · 2026Review
- Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma.Cancer letters · 2026Review
- KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment.Nature reviews. Cancer · 2026Review
- Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer.Cell reports. Medicine · 2026Article
- Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Single-cell and spatial transcriptomic profiling reveals the expression characteristics of PTPRR in epithelial cells and its potential implications in pancreatic cancer metastasis.Frontiers in immunology · 2026Article
- KRAS-driven cytokine-metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma.Frontiers in genetics · 2026Review
- The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities.Nature reviews. Clinical oncology · 2025Review
- Single-dose DSS-induced inflammation enhances colorectal tumorigenesis in APC and KRAS mutant mice.Scientific reports · 2025Article
- Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance.Chinese medical journal · 2025Review
- Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis.NPJ precision oncology · 2025Article
- T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma.Cancer discovery · 2025Article
- Molecular determinants of sotorasib clinical efficacy in KRASNature medicine · 2025Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 1 institution in 1 country.
Pingping HouDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-2429-0861
Avnish KapoorDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Qiang ZhangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jiexi LiDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chang-Jiun WuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0001-8350-6397
Jun LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhengdao LanDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ming TangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-7739-8913
Xingdi MaGraduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-9263-1883
Jeffrey J AckroydGraduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0003-3796-4447
Raghu KalluriDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shan JiangInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Denise J SpringDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-4593-0901
Y Alan WangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. RDePinho@mdanderson.org yalanwang@mdanderson.org.
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. RDePinho@mdanderson.org yalanwang@mdanderson.org.ORCID https://orcid.org/0000-0002-5625-577X
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MExploring Collateral Lethality for Development of Cancer TherapeuticsR01CA225955 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2018 to 2022
$2.3MDeveloping Novel Therapeutic Approaches Targeting Macrophages in GBMR01CA231349 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, Y. ALAN · 2019 to 2024
$1.8MTumor-TAMs crosstalk enables bypass of oncogenic KRAS dependency in pancreatic cancerK22CA251491 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI HOU, PINGPING · 2022 to 2024
$601kNCI NIH HHS K22 CA251491NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA225955NCI NIH HHS R01 CA231349
Abstract
Oncogenic KRAS (KRAS*) is a key tumor maintenance gene in pancreatic ductal adenocarcinoma (PDAC), motivating pharmacologic targeting of KRAS* and its effectors. Here, we explored mechanisms involving the tumor microenvironment (TME) as a potential basis for resistance to targeting KRAS*. Using the inducible
Indexed as
HumansOncogenesPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Tumor MicroenvironmentKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.